China's Humanoid Robot Products Exceed 400 Models, Accounting for Over Half of Global Total
China's 1H25 Innovative Drug Out-Licensing Deal Value Rises to USD110 Billion, Hitting Fresh Record High
China's Outbound Licensing of Innovative Drugs in First Half Nears Last Year's Total
MoneyMasters Podcast: Where to Invest NOW in AI, Biotech, Small Caps, & Gold!
HSI Company: Hang Seng Biotech Index Rebounds 17%+ from Jun Trough as Constituents Step Up Share Buybacks
Guotai Asset Management flags China pharma re-rating as 2026 essential drugs list adds 165 medicines